Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
BakerHostetler says it advised Summit on AstraZeneca’s $2 billion equity investment
BakerHostetler said it advised Summit Therapeutics on AstraZeneca’s $2 billion equity investment through convertible preferred shares. The firm said the transaction closed on October 5 and accompanied a clinical collaboration to evaluate sonesitatug vedotin in combination with ivonescimab for potential gastrointestinal cancer studies.
Key points
- BakerHostetler said Adam Finerman led its team with Alexander Davis and Sean Cheatle.BakerHostetler
- The firm described sonesitatug vedotin as a potential first-in-class Claudin 18.2-targeting antibody-drug conjugate.BakerHostetler
- BakerHostetler said several gastrointestinal cancer trials involving that drug are underway.BakerHostetler
- The firm described ivonescimab as an investigational PD-1/VEGF bispecific antibody.BakerHostetler